$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000139681414000013 Filed on October 30, 2014

Income Statement

Concept	2014 Q3	2013 Q3
Revenue	$52.05M	$23.26M
YoY Change	123.78%	174.09%
Cost Of Revenue	$20.39M	$14.79M
YoY Change	37.86%	59.27%
Gross Profit	$31.66M	$8.468M
YoY Change	273.84%	-1157.18%
Gross Profit Margin	60.82%	36.41%
Selling, General & Admin	$28.22M	$15.32M
YoY Change	84.18%	34.65%
% of Gross Profit	89.13%	180.92%
Research & Development	$4.425M	$5.962M
YoY Change	-25.78%	69.04%
% of Gross Profit	13.98%	70.41%
Depreciation & Amortization	$2.300M	$800.0K
YoY Change	187.5%	-11.11%
% of Gross Profit	7.27%	9.45%
Operating Expenses	$53.03M	$36.07M
YoY Change	47.02%	49.11%
Operating Profit	-$985.0K	-$12.81M
YoY Change	-92.31%	-18.41%
Interest Expense	$2.037M	$1.892M
YoY Change	7.66%	314.91%
% of Operating Profit
Other Income/Expense, Net	-$2.019M	-$1.970M
YoY Change	2.49%	4951.28%
Pretax Income	-$3.004M	-$14.78M
YoY Change	-79.68%	-6.1%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.004M	-$14.78M
YoY Change	-79.68%	-6.1%
Net Earnings / Revenue	-5.77%	-63.56%
Basic Earnings Per Share	-$0.08	-$0.44
Diluted Earnings Per Share	-$0.08	-$0.44
COMMON SHARES
Basic Shares Outstanding	35.94M shares	33.36M shares
Diluted Shares Outstanding	35.94M shares	33.36M shares

Balance Sheet

Concept	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$149.7M	$81.80M
YoY Change	83.01%	22.27%
Cash & Equivalents	$17.76M	$3.383M
Short-Term Investments	$132.0M	$78.50M
Other Short-Term Assets	$5.300M	$4.500M
YoY Change	17.78%	18.42%
Inventory	$23.66M	$15.61M
Prepaid Expenses
Receivables	$20.52M	$9.771M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$199.2M	$111.7M
YoY Change	78.39%	31.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.15M	$45.94M
YoY Change	22.21%	30.08%
Goodwill	$22.05M	$9.539M
YoY Change	131.14%	17.63%
Intangibles
YoY Change
Long-Term Investments	$24.50M
YoY Change
Other Assets	$2.948M	$3.557M
YoY Change	-17.12%	549.09%
Total Long-Term Assets	$106.2M	$60.71M
YoY Change	74.85%	27.28%
TOTAL ASSETS
Total Short-Term Assets	$199.2M	$111.7M
Total Long-Term Assets	$106.2M	$60.71M
Total Assets	$305.4M	$172.4M
YoY Change	77.15%	29.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.747M	$1.559M
YoY Change	396.92%	-67.45%
Accrued Expenses	$23.38M	$15.57M
YoY Change	50.15%	19.46%
Deferred Revenue
YoY Change
Short-Term Debt	$102.1M	$97.90M
YoY Change	4.29%
Long-Term Debt Due	$600.0K	$900.0K
YoY Change	-33.33%	12.5%
Total Short-Term Liabilities	$135.2M	$117.0M
YoY Change	15.6%	489.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$5.235M	$2.911M
YoY Change	79.84%	21.34%
Total Long-Term Liabilities	$5.235M	$2.911M
YoY Change	79.84%	-89.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$135.2M	$117.0M
Total Long-Term Liabilities	$5.235M	$2.911M
Total Liabilities	$150.3M	$123.3M
YoY Change	21.94%	135.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$315.9M	-$284.5M
YoY Change	11.06%	31.59%
Common Stock	$36.00K	$34.00K
YoY Change	5.88%	6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$2.000K
YoY Change		0.0%
Treasury Stock Shares	0.000 shares	1.065K shares
Shareholders Equity	$155.1M	$49.12M
YoY Change
Total Liabilities & Shareholders Equity	$305.4M	$172.4M
YoY Change	77.15%	29.79%

Cashflow Statement

Concept	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$3.004M	-$14.78M
YoY Change	-79.68%	-6.1%
Depreciation, Depletion And Amortization	$2.300M	$800.0K
YoY Change	187.5%	-11.11%
Cash From Operating Activities	$8.980M	-$9.840M
YoY Change	-191.26%	-11.99%
INVESTING ACTIVITIES
Capital Expenditures	-$4.950M	-$4.700M
YoY Change	5.32%	-24.92%
Acquisitions
YoY Change
Other Investing Activities	-$96.86M	$8.310M
YoY Change	-1265.58%	86.74%
Cash From Investing Activities	-$101.8M	$3.610M
YoY Change	-2919.94%	-299.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.380M	980.0K
YoY Change	142.86%	292.0%
NET CHANGE
Cash From Operating Activities	8.980M	-9.840M
Cash From Investing Activities	-101.8M	3.610M
Cash From Financing Activities	2.380M	980.0K
Net Change In Cash	-90.44M	-5.250M
YoY Change	1622.67%	-58.79%
FREE CASH FLOW
Cash From Operating Activities	$8.980M	-$9.840M
Capital Expenditures	-$4.950M	-$4.700M
Free Cash Flow	$13.93M	-$5.140M
YoY Change	-371.01%	4.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7747000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3069000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14590000	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20517000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23383000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17885000	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17491000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12576000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-31000	USD
	us-gaap	Interest Paid InterestPaid	3157000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	337639000	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	470975000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17199000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3777000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8227000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17199000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7686000	USD
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2924000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3104000	USD
CY2013Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	USD
CY2014Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7638000	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8467000	shares
CY2013Q4	us-gaap	Assets Assets	169820000	USD
CY2014Q3	us-gaap	Assets Assets	305394000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	106751000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	199240000	USD
CY2013Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	59632000	USD
CY2014Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	156491000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17756000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12515000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3383000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10126000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36021855	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33636442	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36021855	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33636442	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2965000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14781000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19515000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51963000	USD
CY2013Q4	us-gaap	Convertible Debt ConvertibleDebt	120000000	USD
CY2014Q3	us-gaap	Convertible Debt ConvertibleDebt	120000000	USD
CY2013Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	98961000	USD
CY2014Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	102065000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	20391000	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	14791000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	36396000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	58472000	USD
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3600000	shares
CY2014Q3	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days DebtInstrumentConvertibleThresholdConsecutiveTradingDays	P30D
CY2014Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.3
CY2014Q3	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	20	D
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	21039000	USD
CY2014Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	17935000	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1426000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1008000	USD
CY2014Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9864000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3212000	USD
CY2013Q3	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	2500000	USD
CY2014Q3	us-gaap	Depreciation Depreciation	2300000	USD
	us-gaap	Depreciation Depreciation	6700000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4047000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7328000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13843000	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14517000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	483000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1157000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-157000	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3398000	USD
CY2014Q3	us-gaap	Goodwill Goodwill	22048000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	10328000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	8000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52395000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3004000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14784000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19518000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-442000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10176000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6421000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5419000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5927000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-729000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7070000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8105000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3529000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	735000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2142000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	638000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	696000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	452000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	196000	USD
CY2014Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	100000	USD
CY2013Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	300000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	300000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	900000	USD
	us-gaap	Interest Expense InterestExpense	5325000	USD
	us-gaap	Interest Expense InterestExpense	6222000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	1892000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	2037000	USD
	us-gaap	Interest Paid InterestPaid	4873000	USD
CY2014Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4320000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3946000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	15557000	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	23662000	USD
CY2014Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	8944000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5290000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6321000	USD
CY2014Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10398000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	134000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	207000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	62000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	237000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	150322000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	128571000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169820000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	305394000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	121943000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	135223000	USD
CY2014Q3	us-gaap	Long Term Debt LongTermDebt	102065000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	98961000	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2014Q3	us-gaap	Long Term Investments LongTermInvestments	24527000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	5241000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6743000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88352000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116139000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-123356000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-58159000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	12458000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-36936000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-14784000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-51953000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3004000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19518000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1970000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6435000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2019000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8925000	USD
	us-gaap	Operating Expenses OperatingExpenses	148959000	USD
	us-gaap	Operating Expenses OperatingExpenses	95456000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	36073000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	53033000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13083000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12814000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43470000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-985000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	39245000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5725000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5578000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5436000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5297000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	15965000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1244000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3402000	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2948000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	39000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3190000	USD
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5235000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-120000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	7191000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	24465000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14777000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9368000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	140410000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	102114000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3504000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2819000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	120000000	USD
CY2014Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	110400000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	68016000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	54564000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3043000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5732000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	60758000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73639000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56148000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48182000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	27500000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5962000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14844000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4425000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16724000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1633000	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1829000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315947000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-296429000	USD
CY2014Q3	us-gaap	Revenues Revenues	52048000	USD
	us-gaap	Revenues Revenues	51986000	USD
CY2013Q3	us-gaap	Revenues Revenues	23259000	USD
	us-gaap	Revenues Revenues	135876000	USD
	us-gaap	Royalty Expense RoyaltyExpense	330000	USD
CY2014Q3	us-gaap	Royalty Expense RoyaltyExpense	73000	USD
	us-gaap	Royalty Expense RoyaltyExpense	379000	USD
CY2013Q3	us-gaap	Royalty Expense RoyaltyExpense	132000	USD
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	608000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	1737000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	2249000	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	771000	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	22408000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	132697000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	50920000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	49520000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75643000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15320000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28217000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42336000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17199000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8227000	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3777000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	7686000	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	8129537	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1663835	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	6465702	shares
CY2014Q3	us-gaap	Share Price SharePrice	96.92
CY2014Q2	us-gaap	Share Price SharePrice	64.00
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	59637000	USD
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	131972000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2014Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1840000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5732000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	155072000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41249000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35943000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35039000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33051000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33360000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33051000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35943000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35039000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33360000	shares
	pcrx	Additional Sharebased Compensation Exepnse AdditionalSharebasedCompensationExepnse	200000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	337000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	365000	USD
	pcrx	Antidilutive Securities Excludedfrom Computationof Earnings Per Share Amount Treasury Stock Method AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareAmountTreasuryStockMethod	5300000	shares
CY2014Q3	pcrx	Antidilutive Securities Excludedfrom Computationof Earnings Per Share Amount Treasury Stock Method AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareAmountTreasuryStockMethod	5600000	shares
	pcrx	Antidilutive Securities Excludedfrom Computationof Earnings Per Share Amount Treasury Stock Method AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareAmountTreasuryStockMethod	2800000	shares
CY2013Q3	pcrx	Antidilutive Securities Excludedfrom Computationof Earnings Per Share Amount Treasury Stock Method AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareAmountTreasuryStockMethod	3700000	shares
CY2013Q4	pcrx	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	13000	USD
CY2014Q3	pcrx	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	82000	USD
CY2013Q4	pcrx	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	8000	USD
CY2014Q3	pcrx	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	74000	USD
CY2013Q3	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	243000	USD
CY2014Q3	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	357000	USD
	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	930000	USD
	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	729000	USD
	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	0	USD
CY2014Q3	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	107000	USD
	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	107000	USD
CY2013Q3	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	0	USD
CY2014Q3	pcrx	Compensationexpensefromstockoptions Compensationexpensefromstockoptions	7579000	USD
	pcrx	Compensationexpensefromstockoptions Compensationexpensefromstockoptions	8227000	USD
CY2013Q3	pcrx	Compensationexpensefromstockoptions Compensationexpensefromstockoptions	3777000	USD
	pcrx	Compensationexpensefromstockoptions Compensationexpensefromstockoptions	17092000	USD
CY2012Q2	pcrx	Contingent Payment Obligation Established For Sale Of Product In Connection With Acquisition ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition	2000000	USD
CY2014Q3	pcrx	Debt Instrument Convertible Conversion Premium Shares DebtInstrumentConvertibleConversionPremiumShares	3600000	shares
CY2014Q3	pcrx	Debt Instrument Convertible Conversion Value DebtInstrumentConvertibleConversionValue	349000000	USD
CY2014Q3	pcrx	Employee Stock Purchase Plan Espp Sharesin Espp EmployeeStockPurchasePlanESPPSharesinESPP	500000	shares
	pcrx	Employee Stock Purchase Plan Numberof Shares Authorized EmployeeStockPurchasePlanNumberofSharesAuthorized	500000	shares
	pcrx	Employee Stock Purchase Plan Numberof Shares Available For Purchase EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase	500000	shares
CY2014Q3	pcrx	Employee Stock Purchase Planfairvalue EmployeeStockPurchasePlanfairvalue	0.85
	pcrx	Equity Premium Convertible Debt EquityPremiumConvertibleDebt	0	USD
	pcrx	Equity Premium Convertible Debt EquityPremiumConvertibleDebt	24936000	USD
	pcrx	Goodwill Recordedfor Earn Out Payments GoodwillRecordedforEarnOutPayments	3720000	USD
	pcrx	Goodwill Recordedon Milestone Payments GoodwillRecordedonMilestonePayments	8000000	USD
	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	641000	USD
	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	336000	USD
CY2013Q4	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	100207000	USD
CY2014Q3	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	602000	USD
CY2014Q3	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	102667000	USD
CY2013	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2012Q2	pcrx	Payment Obligation Arising Due To First Commercial Sale Of Product In Connection With Acquisition PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition	10000000	USD
	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	11720000	USD
	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	1241000	USD
	pcrx	Proceeds From Sale Of Unused Net Operating Losses ProceedsFromSaleOfUnusedNetOperatingLosses	400000	USD
CY2013Q4	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	1246000	USD
CY2013Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	1020000	USD
CY2014Q3	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	602000	USD
CY2013Q4	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	226000	USD
CY2014Q3	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	0	USD
	pcrx	Stock Issued During Period Proceeds Followon Public Offering Issues StockIssuedDuringPeriodProceedsFollowonPublicOfferingIssues	0	USD
	pcrx	Stock Issued During Period Proceeds Followon Public Offering Issues StockIssuedDuringPeriodProceedsFollowonPublicOfferingIssues	110407000	USD
	pcrx	Stock Issued During Period Value Follow On Public Offering Issues StockIssuedDuringPeriodValueFollowOnPublicOfferingIssues	110407000	USD
CY2014Q3	pcrx	Total Goodwill Recordedfor Earn Out Payments TotalGoodwillRecordedforEarnOutPayments	6100000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36055639	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.

Files In Submission

Name	View Source	Status
0001396814-14-000013-index-headers.html	Edgar Link	pending
0001396814-14-000013-index.html	Edgar Link	pending
0001396814-14-000013.txt	Edgar Link	pending
0001396814-14-000013-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
pcrx-20140930.xml	Edgar Link	completed
pcrx-20140930.xsd	Edgar Link	pending
pcrx-20140930_cal.xml	Edgar Link	unprocessable
pcrx-20140930_def.xml	Edgar Link	unprocessable
pcrx-20140930_lab.xml	Edgar Link	unprocessable
pcrx-20140930_pre.xml	Edgar Link	unprocessable
pcrx-93014xex101.htm	Edgar Link	pending
pcrx-93014xex311.htm	Edgar Link	pending
pcrx-93014xex312.htm	Edgar Link	pending
pcrx-93014xex321.htm	Edgar Link	pending
pcrx-93014xex322.htm	Edgar Link	pending
pcrx-9302014x10xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2014 Q3 Form 10-Q Financial Statement

#000139681414000013 Filed on October 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2014 Q3 Form 10-Q Financial Statement

#000139681414000013 Filed on October 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx